The global demand for Cell And Gene Therapy Clinical Trials Market is presumed to reach the market size of nearly USD 31.4 MN by 2028 from USD 7.5 MN in 2021 with a CAGR of 19.6% under the study period 2022 - 2028.
Cell and gene therapies clinical trials have quickly emerged as one of the most transformative innovations in biopharmaceuticals. CGTs are tested in therapeutic areas beyond their initial oncology focus, including neurology and ophthalmology treatment. Cell and gene therapy clinical trials present a new wave of innovation in the life sciences industry.
The rise in the CGT pipeline is the root cause fuelling the market growth rate. Also, increasing funding, investments in research and development, and successful product launches are boosting the market growth. Moreover, the market of cell and gene therapy clinical trials has witnessed significant growth over the past few years, with pharma firms partnering to create effective and accessible therapies for patients. Furthermore, cell and gene therapy clinical studies increased significantly compared to last year, as researchers are now shifting their focus to gene therapy because of its potential to treat cancer or rare diseases. This shift is expected to fuel the market growth.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cell and gene therapy clinical trials. The growth and trends of cell and gene therapy clinical trials industry provide a holistic approach to this study.
This section of the cell and gene therapy clinical trials market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Phase
By Indication
This section covers the regional outlook, which accentuates current and future demand for the Cell And Gene Therapy Clinical Trials market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cell and gene therapy clinical trials market include IQVIA, ICON Plc, Laboratory Corporation of America Holdings, Charles River Laboratories International, Inc., PAREXEL International Corp., Syneos Health, Medpace, Holdings, Inc., PPD Inc., Novotech, Veristat LLC. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
Avail customized purchase options to meet your exact research needs: